COVID-19

Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference

CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical…

2 years ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) --  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively…

2 years ago

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio…

2 years ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024…

2 years ago

BioCryst Launches ORLADEYO® (berotralstat) in Italy

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines…

2 years ago

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial…

2 years ago

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprint Company to discontinue sales of radiofrequency ablation and…

2 years ago

NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning…

2 years ago

NanoViricides Has Filed its Quarterly Report – NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum…

2 years ago